Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

about

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

Item

http://www.wikidata.org/entity/Q28076023

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@ast

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@en

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@nl

type

Item

label

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@ast

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@en

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@nl

prefLabel

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@ast

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@en

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@nl

P1476

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma

@en

P2093

Chiemeka Ike

http://www.w3.org/2001/XMLSchema#string

Claire M Mach

http://www.w3.org/2001/XMLSchema#string

Heather Miller

http://www.w3.org/2001/XMLSchema#string

Jennifer Parma

http://www.w3.org/2001/XMLSchema#string

Ramya P Masand

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Cancer statistics, 2015

Clinically Relevant Molecular Subtypes in Leiomyosarcoma

Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.

P304

7018106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3461849

http://www.w3.org/2001/XMLSchema#string

P356

10.1155/2016/7018106

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2016

http://www.w3.org/2001/XMLSchema#string

P50

Matthew L. Anderson

P577

2016-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27721667

http://www.w3.org/2001/XMLSchema#string

P932

5046025

http://www.w3.org/2001/XMLSchema#string